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ABSTRACT 
Renal calcification (RCALC) resulting in nephrolithiasis and nephrocalcinosis, which affects 
~10% of adults by 70 years of age, involves environmental and genetic etiologies. Thus, 
nephrolithiasis and nephrocalcinosis occurs as an inherited disorder in ~65% of patients, and 
may be associated with endocrine and metabolic disorders including: primary 
hyperparathyroidism, hypercalciuria, renal tubular acidosis, cystinuria, and hyperoxaluria. 
Investigations of families with nephrolithiasis and nephrocalcinosis have identified some 
causative genes, but further progress is limited as large families are unavailable for genetic 
studies. We therefore embarked on establishing mouse models for hereditary nephrolithiasis 
and nephrocalcinosis by performing abdominal X-rays to identify renal opacities in N-ethyl-
N-nitrosourea (ENU)-mutagenized mice. This identified a mouse with RCALC inherited as 
an autosomal dominant trait, designated RCALC type 2 (RCALC2). Genome-wide mapping 
located the Rcalc2 locus to a ~16Mbp region on chromosome 11D-E2 and whole-exome 
sequence analysis identified a heterozygous mutation in the DNA polymerase gamma-2, 
accessory subunit (Polg2) resulting in a nonsense mutation, Tyr265Stop (Y265X), which co-
segregated with RCALC2. Kidneys of mutant mice (Polg2
+/Y265X
) had lower POLG2 mRNA 
and protein expression, compared to wild-type littermates (Polg2
+/+
). The Polg2
+/Y265X
 and 
Polg2
+/+
 mice had similar plasma concentrations of sodium, potassium, calcium, phosphate, 
chloride, urea, creatinine, glucose and alkaline phosphatase activity; and similar urinary 
fractional excretion of calcium, phosphate, oxalate and protein. Polg2 encodes the minor 
subunit of the mitochondrial DNA (mtDNA) polymerase and the mtDNA content in 
Polg2
+/Y265X
 kidneys was reduced compared to Polg2
+/+ 
mice, and cDNA expression profiling  
revealed differential expression of 26 genes involved in several biological processes 
including mitochondrial DNA function, apoptosis and ubiquitination, the complement 
pathway, and inflammatory pathways. In addition, plasma of Polg2
+/Y265X
 mice, compared to 
Polg2
+/+
 littermates had higher levels of reactive oxygen species. Thus, our studies have 
identified a mutant mouse model for inherited renal calcification associated with a Polg2 
nonsense mutation.          
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INTRODUCTION 
Renal calcification, which comprises nephrocalcinosis and nephrolithiasis (kidney stones), 
has a multi-factorial etiology involving environmental and genetic determinants
(1)
. 
Nephrocalcinosis and nephrolithiasis, which are calcification of the renal parenchyma and 
collecting system, respectively, affect up to 10% of the adult population by the age of 70 
years
(1-3)
. Over 80% of kidney stones are composed of calcium complexed with oxalate or 
apatite, which form when urine becomes supersaturated with salts such as calcium oxalate or 
calcium phosphate or when concentrations of stone inhibitors such as citrate, uromodulin and 
osteopontin are reduced
(1,4,5)
. Nephrolithiasis and nephrocalcinosis are often associated with  
endocrine and metabolic disorders including: primary hyperparathyroidism, hypercalciuria, 
renal tubular acidosis, cystinuria, low urinary volume and hyperoxaluria
(2,4)
. However, ~30% 
of individuals with kidney stones have no obvious metabolic defect and these patients are 
designated as having idiopathic nephrolithiasis
(2,4,6,7)
.  
Evidence for a genetic contribution to these renal calcification disorders has been provided by 
family and twin studies. Thus, up to 65% of kidney stone patients have an affected family 
member
(8,9)
 and twin studies have estimated the heritability of hypercalciuria
(10)
 and kidney 
stones
(11)
 to be 52% and 56%, respectively. Studies of families with rare monogenic disorders 
associated with hypercalciuric nephrolithiasis and/or nephrocalcinosis, such as Bartter’s 
syndrome, Dent’s disease, autosomal dominant hypocalcaemia, and distal renal tubular 
acidosis have identified mutations in >30 genes involved in calcium transport regulation 
(Table S1)
(3,12,13)
. Furthermore, genome-wide association studies and targeted sequencing of 
genes with known roles in calcium and vitamin D metabolism have identified associations 
between nephrolithiasis and common sequence variants in >10 additional genes (Table 
S1)
(1,14-16)
. However, these account for only ~15-20% of cases
(3,12)
, and the identification of 
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further monogenic causes of nephrolithiasis are limited by the unavailability of large families. 
To overcome these difficulties and facilitate the identification of genetic abnormalities 
causing idiopathic nephrolithiasis and nephrocalcinosis, we embarked on establishing mouse 
models for renal calcification by investigating the phenotypes of progeny of mice treated with 
the chemical mutagen N-ethyl-N-nitrosourea (ENU). ENU is an alkylating agent that 
primarily introduces point mutations via transfer of the ENU alkyl group to the DNA base 
followed by mispairing and subsequent base pair substitution during the next round of DNA 
replication
(17,18)
. In phenotype-driven screens, offspring of mutagenized mice are assessed for 
abnormalities in a hypothesis-generating strategy, which may elucidate new genes, pathways, 
and mechanisms for disease phenotypes
(17,18)
. ENU mutagenesis has generated a variety of 
mouse models for metabolic and renal disorders including a mouse model for renal failure 
due to a substitution in aquaporin-11
(19)
, and a mouse model for idiopathic hypercalciuria
(20)
. 
Here, we report an ENU-induced mouse model of renal calcification (RCALC), that is 
referred to as RCALC type 2 (RCALC2), and is associated with a Tyr265Stop (Y265X) 
nonsense mutation in the DNA polymerase subunit gamma-2, accessory protein (Polg2), 
which functions in the replication of mitochondrial DNA (mtDNA)-encoded proteins.    
  
MATERIALS AND METHODS 
Animals 
Animal studies were carried out using guidelines issued by the UK Medical Research Council 
in Responsibility in Use of Animals for Medical Research (July 1993) and UK Home Office 
project licence numbers (30/2250 and 30/2752). ENU-treated G0 BALB/c male mice were 
mated to female C3H/HeH (C3H) mice to produce first generation (G1) progeny. Male G1 
offspring were X-rayed for renal opacities and sperm archived
(20)
. Archived RCALC2 
founder male sperm was used for in vitro fertilisation (IVF) of C3H oocytes to derive G2 
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animals
(20)
. Mice were fed on a standard diet (Rat and Mouse number 3, Special Diet 
Services, Essex, UK) that contained 1.15% calcium, 0.58% phosphate, and 4089 IU/kg of 
vitamin D, and provided with water ad libitum
(21)
.  
 
Metabolic cage studies, plasma and urine biochemistry 
Adult (16-week old) G2 mice were individually housed in metabolic cages (Techniplast, 
Louviers, France) for 5 days with free access to food and water
(22)
. Mice were weighed before 
and after the study, and food and water intake was monitored. Twenty-four-hour urine 
samples were collected in the presence of sodium azide and blood samples were collected 
from lateral tail vein or the internal jugular vein in lithium heparin Microvette tubes (Sarstedt, 
Leicester, UK) following terminal anaesthesia, as previously described
(22)
. Plasma and urine 
were appropriately analyzed for sodium, potassium, chloride, total calcium, phosphate, urea, 
glucose, creatinine, oxalate, total protein, albumin and alkaline phosphatase activity on a 
Beckman Coulter AU680 analyzer
(21)
. Plasma calcium was adjusted for variations in albumin 
concentrations using the formula: (plasma calcium (mmol/L) − [(plasma albumin 
(g/L) − 30) × 0.02], as reported(21). The fractional excretion of calcium and phosphate were 
calculated using the formula Ux/Px*PCr/UCr, where Ux is the urinary concentration of the 
filtered substance (substance x) in mmol/L, Px is the plasma concentration of substance x in 
mmol/L, UCr is the urinary concentration of creatinine in mmol/L, and PCr is the plasma 
concentration of creatinine in µmol/L
(21)
. A Kruskal-Wallis test was undertaken for multiple 
comparisons, and any significant differences identified were further assessed using the 
Dunn’s test for nonparametric pairwise multiple comparisons. All analyses were undertaken 
using GraphPad Prism software, and a value of p<0.05 was considered significant for all 
analyses. 
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Kidney histology and immunohistochemistry 
Kidneys were obtained from adult (16-33-week old) mice, halved, fixed in 10% neutral-
buffered formalin overnight, and embedded in paraffin wax. Four-µm serial sections were 
prepared and stained with either: haematoxylin and eosin, von Kossa, or Masson’s 
Trichrome, as described previously
(20)
. Images were collected on a Nikon Eclipse E400 
microscope (Kingston-upon-Thames, UK), equipped with a Nikon DXM1200C digital 
camera. Measurements of calcified regions were performed using the Nikon Eclipse E400 
software.  
 
Genetic mapping  
Genomic DNA was isolated from tail biopsies using the Gentra PureGene kit (Qiagen, 
Manchester, UK) and genome-wide scans performed by pyrosequencing
(23)
 using a panel of 
59 informative SNPs distributed across 19 autosomes, at 20-30cM intervals. Polymorphic 
positions were analyzed using a PSQ-96 system (Qiagen)
(20)
. Chromosomal linkage was 
verified by non-inheritance of BALB/c alleles of SNPs of interest in 13 unaffected 
littermates. G2 and G3 mice were genotyped for additional markers within the critical region. 
 
Exome sequence analysis 
Sequencing libraries were constructed using the NimbleGen kit (Roche, West Sussex, UK) 
and libraries combined in pools of six for targeted capture, using the SeqCap EZ Mouse 
Exome SR v2.2 (target regions available from 
ftp://ftp.jax.org/Genome_Biology_mouse_exomes). Libraries were assessed pre- and post-
capture for quality and yield, using a High Sensitivity DNA assay (Agilent, Santa Clara, 
California) and Library Quantification Kit (KAPABiosystems, Gillingham, UK). Massive 
parallel sequencing was performed with 6 samples per flow cell lane, using the HiSeq2000 
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platform and SBS reagents (Illumina, San Diego, California) to generate 100bp paired-end 
reads. Illumina Data Analysis Pipeline software (CASAVA 1.8.1) was used for initial base 
calling and data multiplexing.  Illumina reads were mapped to the mouse genome (mm9) 
using the Burrows-Wheeler Aligner (BWA)_v2
(24)
 with the default parameters. Single 
nucleotide variant (SNV) calls were made using a customised version of The Genome 
Analysis Toolkit (GATK)
(25)
 with default parameters. Several triaging steps were made to 
reduce false positives
(26)
. The 17 Mouse Genome dataset
(27)
 was used to filter inbred single 
nucleotide polymorphism (SNPs) sites from the RCALC2 SNV dataset, and common sites 
were removed from further investigation. The remaining SNVs were further filtered by 
removing sites with an allele frequency <35% and >80%, a read depth <3 and a quality score 
>200. The final RCALC2 SNV dataset was annotated with NGS-SNP
(28)
.  
 
DNA sequence analysis 
Variants were validated in G2 mice by Sanger DNA sequencing, using appropriate gene-
specific primers (Sigma, Gillingham, UK), followed by dideoxynucleotide sequencing using 
the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, California) 
and an automated detection system (ABI3730 capillary sequencer; Applied Biosystems, 
Carlsbad, California)
(29)
. DNA samples from G2 and G3 mice were assessed by restriction 
endonuclease analysis using HindIII and BsrDI restriction endonucleases, as described
(20)
.  
 
Protein sequence alignment and protein prediction 
Protein sequences were aligned using ClustalW
(30)
 and the effect of mutations predicted using 
MutationTaster (http://www.mutationtaster.org/)
(31)
.  
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RNA extractions, cDNA expression profiling and quantitative RT-PCR (qRT-PCR) 
analysis  
Total RNA was extracted from kidney samples taken from adult (30-33-week old) RCALC2 
mice or parental wild-type (WT), BALB/c and C3H mice littermates (N=4 - 8 mice per 
group) using Trizol reagent (Invitrogen, Carlsbad, CA). Following DNaseI-treatment, RNA 
was purified using an RNeasy Mini kit (Qiagen). Nine-g total RNA was used for first and 
second-strand cDNA synthesis using the One-Cycle cDNA Synthesis Kit (Affymetrix, High 
Wycombe, UK) according to the manufacturer’s instructions. Biotinylated cRNA was 
synthesized using the Genechip IVT Labelling Kit (Affymetrix). Fifteen-g of fragmented 
cRNA was hybridised for 16 hours at 45C to Mouse Genome 430 2.0 arrays (Affymetrix). 
Following hybridisation the arrays were washed and stained with streptavidin-phycoerythrin 
in the Affymetrix Fluidics Station 450 and scanned using the GeneChip Scanner 3000 7G. 
The image data were analyzed with GCOS 1.4 using Affymetrix default analysis settings and 
global scaling as a normalization method. The dataset of the arrays were normalized using 
Robust Multi-chip Average algorithm in respect to the sequence-specific probe affinities
(32)
. 
Differences between the datasets were investigated using the t-statistic. Genes with a 
significant p-value (p<0.05), and >1.10-fold difference in expression (in the same direction) 
versus both parental strains were selected for further evaluation. qRT-PCR reactions were 
performed in cDNA prepared from the kidneys of 4 - 5 Polg2
+/+
 and 4 Polg2
+/Y265X
 mice 
using the QuantiTect SYBR Green Kit (Qiagen) and utilizing a Rotorgene 5 (Qiagen), as 
previously described
(33)
. All qRT-PCR test samples were normalized to the geometric mean 
of three housekeeper genes (cyclin D1 (Ccnd1), cyclin D2 (Ccnd2) and β-actin (Actb)), as 
described previously
(34)
. ΔCt values were derived by subtracting the Ct value of the 
housekeeping gene from the experimental gene. The average of the ΔCt values was then used 
as a reference to calculate ΔΔCt values. Fold-changes were calculated using the formula 2
-
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(∆∆Ct)
. For mtDNA quantification, mt-ND1 levels were normalized to the nuclear gene β-actin 
(Actb). Threshold cycle (CT) values were obtained from the start of the log phase on 
Rotorgene Q Series Software and CT values analyzed in Microsoft Excel 97–2010 using the 
Pfaffl method
(33-35)
. Statistical analyses were performed using the Student’s t-test.   
 
Analysis of protein expression 
Whole kidney lysates from RCALC2 mutant mice and WT littermate mice were prepared 
using NP40 lysis buffer (50mM Tris-HCl pH7.4, 1mM EDTA, 150mM NaCl, 1% NP40, 
protease inhibitors), resuspended in Laemmli buffer, boiled and separated by sodium-dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), as previously described
(34)
. Blots 
were electro-transferred to polyvinylidene fluoride membranes (Millipore, Abingdon, UK) 
and probed with anti-POLG (SantaCruz), anti-POLG2 (Aviva Systems Biology, San Diego, 
CA) or anti-alpha-tubulin (Abcam, Cambridge, UK) primary antibodies, followed by HRP-
conjugated secondary antibodies (Biorad, Watford, UK). Blots were visualized on a BioRad 
Chemidoc XRS+ system and densitometry performed using ImageJ
(20,33)
. For protein 
detection in urine 1μg/ml samples were resolved on SDS-PAGE gels and stained with 
Coomassie blue solution. 
 
Intracellular reactive oxygen species (ROS) assay 
ROS generation was assessed using the OxiSelect Intracellular ROS assay kit (Cell Biolabs, 
San Diego, CA), according to the manufacturer’s protocol and adapting previously described 
methods
(36)
. Plasma samples from 4 RCALC2 mutant mice and 4 WT littermates were used 
for ROS studies. A standard curve was prepared using the supplied standards. Fluorescence 
was determined using a CytoFluor microplate reader (PerSeptive Biosystems) at 485nm 
excitation and 530nm emission wavelengths, and relative fluorescence units derived from the 
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standard curve. Data was expressed as mean±SEM compared to that of WT, which was 
expressed as 1. Statistical analyses were performed using two-way ANOVA. 
 
Apoptosis assay 
Apoptosis was assessed in whole kidney lysates using the Caspase-Glo 3/7 luminescence 
assay (Promega) measuring levels of active-caspase 3/7, as previously described
(29)
. 
Luminescence was measured using a Turner Biosystems luminometer (Promega). 
Experiments were performed in 10 independent kidney samples each, from RCALC2 mutant 
mice and WT littermates. Data was expressed as fold change±SEM for each group. Statistical 
analyses were performed using two-way ANOVA. 
 
Statistical analysis 
Statistical analyses were performed using the Kruskal-Wallis test, Dunn’s test for 
nonparametric pairwise multiple comparisons, two-way ANOVA and the Student’s t-test.  
 
 
RESULTS 
Identification and characterization of RCALC2, a mouse model for renal calcification  
The RCALC2 founder was identified from a radiological screen for renal opacities in 1,745 
12-month old male G1 offspring of ENU-treated BALB/c males and wild-type C3H/HeH 
(C3H) females. IVF was used to derive 85 G2 mice (48 males (M) and 37 females (F)), using 
sperm from the RCALC2 founder, and 138 G3 mice (68 M and 70 F) were derived from 
matings of G2 mice. Renal calcification was assessed in adult mice (16-33 weeks of age) by 
von Kossa staining of kidney sections, to detect calcium deposits, and haematoxylin and 
11 
 
eosin, to detect tissue morphology of histological sections (Fig. 1A). Calcification was 
predominantly present within the renal papilla and cortex, and was not associated with 
fibrosis, which was assessed by Masson’s Trichrome staining (Fig. S1A). Regions of 
calcification within the renal papilla and cortex were measured and shown to have a mean 
diameter of 20.42 μm (range 10.77 - 43.21 μm) (sections from n = 42 mice). The mean area 
of calcification was estimated to be 381.09 μm2 (range 10.77 – 43.21 μm2). These calcified 
regions were therefore too small to extract high quality material that would allow for 
chemical analysis of stone composition. Forty-three (24 M, 19 F) of the 85 G2 mice (50.6% 
and 60 (33 M, 27 F) of the 138 G3 mice (43.3%)) had renal calcification, yielding affected to 
non-affected ratios in G2 mice = 1:0.98 and G3 mice = 1:1.3, which were not significantly 
different from the 1:1 ratio expected for an autosomal dominant mode of inheritance with 
high penetrance (observed versus expected ratios for G2 mice were 43 affected: 42 
unaffected, versus 42.5 affected:42.5 unaffected (χ2 test, p = 1)), and for G3 mice were 60 
affected:78 unaffected versus 69 affected:69 unaffected (χ2 test, p = 0.28)). In addition, the 
ratio of affected males (M) to affected females (F) for the G2 and G3 mice was 1.3:1 and 
1.2:1, respectively, and consistent with the 1:1 ratio expected for an autosomal dominant 
disorder (observed versus expected ratios for G2 mice were 24 M:19 F versus 21.5 M:21.5 F 
(χ2 test, p = 0.52) and for G3 mice were 33 M:27 F versus 30 M:30 F (χ2 test, p = 0.30)). In 
addition, the ratios of wild-type (i.e. unaffected) males to females for the G2 and G3 mice 
were 1.3:1 and 0.8:1, respectively, and not significantly different to the expected 1:1 ratio for 
an autosomal dominant trait (observed versus expected ratios for G2 mice were 24 M:18 F 
versus 21 M:21 F (χ2 test, p = 0.43)), and for G3 mice were 35 M:43 F versus 39 M:39 F (χ2 
test, p = 0.41)). Furthermore, a backcross of RCALC2 mice onto the C57BL/6 strain resulted 
in 43 (27 males and 16 females) of 65 mice (66.2%) with renal calcification, demonstrating 
that the phenotype is unrelated to background strain. Calcification was absent from heart 
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sections indicating that the observed calcification is tissue-specific, and not associated with 
ectopic calcification in multiple tissues (Fig. S1B). The RCALC2 mice were not observed to 
have any other abnormalities. 
 
Mapping of the Rcalc2 locus to chromosome 11D-E2 and identification of the Polg2 
nonsense mutation by whole-exome sequence analysis 
Genome-wide mapping using DNA samples from 13 affected RCALC2 mice (8 males and 5 
females) and 59 SNP sets revealed co-segregation of the phenotype with BALB/c alleles on 
chromosome 11. Further analysis, in 39 affected mice, demonstrated co-segregation of the 
RCALC2 phenotype with chromosome 11D-E2 loci (peak LOD score = 7.1) that spanned a 
~16Mb region, flanked by D11Mit132 and D11Mit214 (Fig. 1B), and contained over 230 
genes. To identify the RCALC2 causative gene, a whole-exome sequence analysis was 
performed using DNA from two G2 RCALC2 mice, together with two control mice 
consisting of one Balb/c WT mouse and one C3H WT mouse, which would allow the 
inheritance of SNPs from parental mice to be determined. This analysis identified 17 unique 
variants, of which two were located on chromosome 11 (Table S2). None of the 17 variants 
were in genes previously associated with nephrocalcinosis or nephrolithiasis (Table S1). One 
variant was a non-synonymous heterozygous C-to-A transversion at nucleotide c.795 in the 
Polg2 gene. The C-to-A transversion in codon 265 of Polg2 is predicted to result in a change 
of the WT amino acid residue of Tyr265 to a premature stop codon, thereby leading to a 
nonsense mutation (Tyr265Stop, Y265X), and in a gain of a HindIII restriction endonuclease 
site (A/AGCTT) (Fig. 1C). The other variant was a non-synonymous heterozygous change C-
to-A transversion at nucleotide c.1255 in the ADP-ribosylation factor GTPase-activating 
protein (ArfGAP) with coiled-coil, ankyrin repeat and PH domains 1 (Acap1) gene. This 
variant is predicted to cause a missense amino acid change from Gln to Lys at codon 419 
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(Gln419Lys, Q419K), and in a loss of a BsrD1 restriction endonuclease site (GCAATG/NN). 
Bioinformatic analysis using MutationTaster software
(31)
 predicted the Polg2 and Acap1 
variants to be damaging, and studies of G2 mice using HindIII restriction endonuclease 
analysis (Fig. 1D) revealed that RCALC2 co-segregated with the Polg2 mutation, i.e. mice 
with renal calcification that had the Polg2 mutation on the Balb/c allele, whilst mice without 
calcification had the wild-type (C3H) allele (n = 13 tested, data not shown). Further analysis 
of all 85 G2 mice and 138 G3 mice revealed that: 84% of G2 mice with renal calcification, 
and 71% of G3 mice with renal calcification had the Tyr265Stop Polg2 mutation (Table 1), 
indicating that the mutation, which co-segregates with the phenotype (Table 1), had a reduced 
penetrance. In contrast, only 50% of G2 mice with renal calcification, and 50% of G3 mice 
with renal calcification had the Glu419Lys Acap1 mutation, demonstrating that the mutation 
does not co-segregate with the phenotype (Table 1). Thus, the Polg2-Y265X variant co-
segregates with RCALC2, and the metabolic phenotype of mice with this mutation was 
investigated in further detail. 
 
Metabolic analysis of mice with the Polg2-Tyr265Stop mutation 
Renal calcification is often associated with metabolic abnormalities including hypercalciuria, 
and we therefore performed biochemical analyses of plasma and urine samples from WT 
(Polg2
+/+
) and heterozygous mutant Polg2 (Polg2
+/Y265X
) mice
(2,4,6,7)
. Polg2
+/Y265X
 mice were 
fertile, grew at similar rates as their Polg2
+/+ 
littermates, had similar body weights (data not 
shown), and appeared morphologically normal. Analyses of plasma and urine samples from 
Polg2
+/+
 and Polg2
+/Y265X
 adult mice, aged 16 weeks, revealed no significant differences 
between Polg2
+/Y265X
 and Polg2
+/+
 mice in plasma concentrations of sodium, potassium, 
albumin-adjusted calcium, chloride, urea, creatinine, glucose, phosphate, or alkaline 
phosphatase activity (Table 2). Furthermore, there were no significant differences between 
14 
 
Polg2
+/+
 and Polg2
+/Y265X
 mice in urine output or urinary excretion of calcium, phosphate or 
oxalate which have previously been associated with renal calcinosis
(37)
 (Table 3). In addition, 
the excretion of total protein was not significantly different between the two groups, and 
urinary protein analysis examined by Coomassie Blue stain, revealed no difference between 
Polg2
+/+
 and Polg2
+/Y265X
 mice (Table 3 and Fig. S2), suggesting that a Fanconi-like 
syndrome with proteinuria is not associated with the renal calcification. Therefore, RCALC2 
is likely to represent a model of idiopathic nephrolithiasis and nephrocalcinosis. 
 
RCALC2 kidneys have reduced POLG2 expression 
The Polg2 gene encodes the 459 amino acid POLG2 protein, and the premature stop codon is 
predicted to lead to loss of the C-terminal 194 residues that are highly conserved in the 
mutant POLG2 protein (Fig. S3). Thus, the POLG2 Tyr265Stop mutation could be predicted 
to result in protein reduction, due to nonsense-mediated decay of the mutant transcript, 
folding errors and subsequent endoplasmic reticulum (ER) retention, or a severely truncated 
protein. To investigate the effect of the Tyr265Stop mutation on POLG2 cDNA expression, 
total RNA was extracted from kidneys of Polg2
+/+
 and Polg2
+/Y265X
 mice, and qRT-PCR 
performed using primers that bind within the first 264 amino acids of Polg2, to quantify 
Polg2 content (Fig. 2A). Renal Polg2 cDNA transcript levels were significantly reduced in 
Polg2
+/Y265X
 mice compared to Polg2
+/+
 mice (p<0.05, Fig. 2A). Furthermore, analysis of 
renal expression of the POLG2 protein by Western blot and densitometry analysis revealed 
that Polg2
+/Y265X
 mice had significantly reduced expression of POLG2 protein, compared to 
Polg2
+/+
 mice (Fig. 2B and Fig. S4). In contrast, the renal expression of the DNA polymerase 
subunit gamma (POLG) protein, which forms a heterotrimer with two subunits of POLG2 to 
form the functional mtDNA polymerase
(38)
, was expressed at similar levels in Polg2
+/+
 and 
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Polg2
+/Y265X
 mice (Fig. 2C and Fig. S4). Therefore, the Tyr265Stop mutation reduces POLG2 
cDNA and protein levels and this may affect mitochondrial functions.  
 
mtDNA levels and function 
POLG2 encodes the minor subunit of the mitochondrial DNA (mtDNA) polymerase, which is 
responsible for DNA replication of 13 proteins, 22 tRNAs and 2 rRNAs that are required for 
transcription of mitochondria-specific proteins, including those involved in oxidative 
phosphorylation
(39)
. Furthermore, patients with mutations of POLG2, who have progressive 
external ophthalmoplegia (PEO), have reduced mtDNA content in their cells
(40)
. We therefore 
hypothesized that the Polg2-Y265X mutation may affect the mtDNA content in Polg2
+/Y265X
 
kidneys and compared this with the Polg2
+/+
 kidneys (Fig. 3A). The copy number of mtDNA 
was assessed by qRT-PCR of the mitochondrially encoded NADH-ubiquinone 
oxidoreductase core subunit 1 (mt-Nd1) gene and compared to expression levels of the 
nuclear gene β-actin (Actb) (Fig. 3A). The mtDNA copy number of Polg2+/Y265X mice was 
significantly reduced compared to Polg2
+/+
 mice (Fig. 3A).  
As the mtDNA content of Polg2
+/Y265X
 mice was reduced, we hypothesized that other genes 
involved in mitochondrial function may also be affected by the Polg2
+/Y265X
 mutation. We 
therefore assessed expression of all genes in kidneys from Polg2
+/Y265X
 and parental Balb/c 
and C3H mice by cDNA expression profiling. This revealed 26 genes to be differentially 
expressed (p<0.05, fold change >1.10) between Polg2
+/Y265X
 and parental Balb/c and C3H 
mice (Polg2
+/+
) (Table S3). Of these 26 genes, 13 genes were significantly upregulated and 
13 genes were significantly downregulated in Polg2
+/Y265X
 kidneys compared to parental 
Balb/c and C3H kidneys (Table S3). Further analyses revealed that these genes fell into eight 
broad categories of biological function including genes involved in: mitochondrial DNA 
function (n = 5), in which POLG2 is known to be essential; complement pathway 
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components (n = 3); inflammatory pathways (n = 4); and apoptosis and ubiquitination (n = 4), 
which may be activated by damaged mitochondria
(37)
. Changes in gene transcription were 
validated by qRT-PCR analysis in kidney cDNA samples from four Polg2
+/+
 and four 
Polg2
+/Y265X
 mice (Fig. 3B-H and Table S4). Thus, the differential expression of one 
upregulated gene (ubiquitin-conjugating enzyme E2 (Ube2c)) involved in ubiquitination (Fig. 
3B); two upregulated genes (complement component 1, q subcomponent, C chain (c1qc) and 
complement component 3 (c3)) that encode components of the complement pathway (Fig. 
3C-D); one upregulated (apolipoprotein M (Apom)) and one downregulated gene 
(peroxisomal membrane protein 4 (Pxmp4)) involved in inflammatory pathways (Fig. 3E-F); 
and one upregulated (mitochondrial ribosomal protein L3 (Mrpl3)) and one downregulated 
gene (glycerol phosphate dehydrogenase 2, mitochondrial (Gpd2)) that are involved in 
mtDNA function (Fig. 3G-H) in Polg2
+/Y265X
 kidneys, were confirmed by qRT-PCR analysis. 
These findings indicate that the Polg2-Y265X mutation affects the expression of genes 
involved in multiple cellular mechanisms. 
 
As the cDNA expression profiling analysis and qRT-PCR validation revealed changes in 
genes encoding proteins important for mtDNA function (Fig. 3 and Table S3), we 
hypothesized that the POLG2-Tyr265Stop mutation may impair mitochondrial processes 
such as oxidative phosphorylation and apoptosis. Disruption of oxidative phosphorylation has 
previously been shown to lead to increases in reactive oxygen species (ROS) within cells, 
rodent models and in patients with nephrolithiasis, and these increases in ROS have been 
hypothesized to contribute to renal cell damage, and consequently crystal retention and 
nephrocalcinosis
(37,41-43)
. To determine if the POLG2-Tyr265Stop mutation increased ROS 
production, we assessed levels of ROS
(36)
 in plasma samples from Polg2
+/+
 and Polg2
+/Y265X
 
mice. Plasma ROS levels were significantly higher in mutant POLG2 Tyr265Stop mice 
(mutant = 1.86±0.20 versus WT = 1.00±0.10, p<0.02) (Fig. 4A), indicating that the Polg2 
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mutation may increase mitochondrial damage and consequently ROS production. We 
hypothesized that this increase in ROS production may be associated with changes in the 
expression of genes involved in oxidative phosphorylation in Polg2
+/Y265X
 mice compared to 
Polg2
+/+
 mice. Therefore, the cDNA transcript levels of two genes, NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex subunit 1 (Ndufa1) and Cytochrome C oxidase subunit 
NDUFA 4 (Ndufa4), which encode components of the mitochondrial oxidative 
phosphorylation complex I and complex IV, respectively
(44,45)
, were assessed in renal cDNA 
samples from Polg2
+/+
 and Polg2
+/Y265X
 mice by qRT-PCR analysis. This revealed reduced 
expression of the Ndufa1 transcript in Polg2
+/Y265X
 kidneys compared to Polg2
+/+
 mice, whilst 
Ndufa4 transcript levels were similar (Fig. 4B and Table S4). Furthermore, assessment of the 
acyl-CoA dehydrogenase medium chain (Acadm) gene that catalyses the first step of the 
mitochondrial β-oxidation pathway, impairments of which have been shown to activate 
oxidative stress
(46)
, were not significantly different between the Polg2
+/+
 and Polg2
+/Y265X
 
mice (Fig. 4C and Table S4). This indicates that the changes in ROS may be associated with 
changes in the expression of complex I components, but are not associated with changes in 
the β-oxidation pathway.   
We next assessed the effect of the POLG2-Tyr265Stop mutation on apoptosis as 
mitochondria play a critical role in this process
(42)
, and genes involved in apoptosis are 
differentially expressed in the kidneys of Polg2
+/Y265X
 mice (Table S3). The apoptotic genes 
identified in the cDNA expression profiling to be differentially expressed do not encode the 
critical components of mitochondrial apoptotic pathways. We therefore assessed the 
expression of apoptotic genes known to directly act within the mitochondrial apoptosis 
pathway. This demonstrated that Cycs, which encodes cytochrome C that mitochondria 
release when triggered by apoptosis
(47)
, was expressed at significantly higher levels in 
kidneys from Polg2
+/Y265X
 mice compared to Polg2
+/+
 (Fig. 4D). Despite this, there was no 
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significant difference in cDNA expression levels of two enzymes, caspase 3 (Casp3) and 
caspase 9 (Casp9), that form part of the cascade that is activated directly by cytochrome C
(47)
 
(Fig. 4D and Table S4). Measurement of active caspase 3/7 using the CaspaseGlo 
chemiluminescent assay and kidneys from Polg2
+/+
 and Polg2
+/Y265X
 mice revealed no 
difference in apoptosis between the two groups consistent with previous findings in Polg2 
heterozygous (Polg2
+/-
) knockout 
 
mice
(48)
 (Fig. 4E and Table S4). Finally, we examined 
whether genes encoding proteins in the phagocytosis pathway, which requires changes in 
mitochondrial membrane potential for engulfment to occur efficiently, were differentially 
expressed in the kidneys of Polg2
+/Y265X
 mice. We assessed the expression of uncoupling 
protein 2 (Ucp2), which regulates mitochondrial membrane potential and is upregulated in 
phagocytes engulfing apoptotic cells, and T Cell Immunoglobulin And Mucin Domain 
Containing 4 (Timd4), an engulfment receptor that recognises apoptotic cells
(49,50)
. Renal 
Ucp2 cDNA transcript levels were significantly increased, while Timd4 was similarly 
expressed in Polg2
+/Y265X
 mice, when compared to Polg2
+/+
 mice (Fig. 4F and Table S4).  
Thus, the Polg2
+/Y265X
 mutation likely has a selective effect on mitochondrial functions.    
 
DISCUSSION 
Our studies have demonstrated that renal calcification in a mutant mouse model is due to a 
heterozygous germline Tyr265Stop mutation of Polg2, which encodes the POLG2 protein 
that forms part of a heterotrimeric complex composed of two POLG2 subunits and one 
catalytic POLG subunit
(39)
. Mutations in both POLG and POLG2 cause diseases in humans, 
referred to as the POLG-related disorders, which have a wide and not well defined spectrum 
of overlapping phenotypes
(51)
. These POLG-related disorders include: childhood 
myocerebrohepatopathy spectrum (MCHS), characterized by developmental delay, lactic 
acidosis, myopathy, failure to thrive, and sometimes liver failure, renal tubular acidosis, 
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pancreatitis, cyclic vomiting and hearing loss
(51)
; Alpers-Huttenlocher Syndrome 
characterized by encephalopathy, intractable seizures, neuropathy and liver failure
(52)
; 
myoclonic epilepsy myopathic sensory ataxia (MEMSA); ataxia neuropathy spectrum (ANS); 
autosomal recessive progressive external opthalmoplegia (ArPEO); and autosomal dominant 
progressive external opthalmoplegia (AdPEO). POLG mutations cause the autosomal 
recessive diseases MCHS, Alpers-Huttenlocher syndrome, MEMSA, ANS and ArPEO, as 
well as AdPEO; whereas POLG2 mutations, which are usually heterozygous, cause AdPEO, 
as well as dysfunctions of the central and/or neuromuscular systems
(40)
. Renal tubular disease 
has been reported only occasionally in MCHS patients with POLG mutations, but not in those 
with POLG2 mutations
(51,53)
. However, assessments for renal calcification may not have been 
undertaken in these patients with POLG2 mutations, and it is important to note that 
individuals heterozygous for POLG2 or POLG mutations have also been reported as having a 
normal phenotype. Moreover, the majority of POLG2 mutations reported to date in humans 
are missense mutations
(54)
 that may act differently to the nonsense Polg2
+/Y265X
 mutation, 
reported in this study of mutant RCALC2 mice. In addition, ocular defects were not observed 
in the Polg2
+/Y265X
 mice, and this is consistent with reports of previous mouse models in 
which heterozygous Polg and Polg2 knockout mice developed normally and had no 
phenotypes associated with mitochondrial disease
(48,55)
. This is in contrast to mice with 
homozygous deletion of Polg and Polg2, which are lethal in early development and by 
embryonic days 7.5-8.5
(48,55)
. These studies therefore indicate that the heterozygous deletions 
of the POLG2 knockout mice and nonsense mutations of the Polg2
+/Y265X
 mice likely act 
differently to the mutations observed in man, which act in a dominant-negative manner
(54)
. As 
our studies showed a reduction in POLG2 protein in the Polg2
+/Y265X
 mice (Fig. 2), indicating 
likely degradation of the mutant product, we did not breed homozygous Polg2
Y265X/Y265X
 mice, 
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as these would likely be embryonically lethal and therefore not provide further information 
about the renal phenotype.   
The Polg2
+/Y265X
 mice have calcification predominantly of the renal papilla and cortex (Fig. 
1), which is consistent with the hypothesis that calcification typically occurs late in the renal 
tubular pathway, following precipitation of calcium crystals
(56,57)
. This precipitation is often 
associated with a metabolic defect such as hypercalciuria; inflammation or damage to 
epithelial layers by aberrant signaling or ROS; or changes in gene expression (e.g. stone 
inhibitors)
(2,4,6,7,43)
. Our studies did not find the Polg2
+/Y265X
 mice to have any metabolic 
defects (Tables 2-3) or tissue damage such as apoptosis and fibrosis (Fig. 4 and Fig. S1), but 
did find aberrant signaling, a rise in ROS and changes in gene expression to be present in the 
kidneys of the Polg2
+/Y265X
 mice (Fig. 2-4). Thus, the Polg2-Tyr265Stop mutation was 
associated with reduced levels of POLG2 (Fig. 2), decreased levels of mtDNA (Fig. 3), 
changes in expression of genes encoding components of mitochondrial specific processes 
(including mitochondrial ribosomal proteins (Mrpl3), components of the electron transport 
chain and oxidative phosphorylation complex I (Gpd2 and Ndufa1), and phagocytosis (Ucp2) 
(Fig. 3 and 4)), and an increase in production of ROS (Fig. 4). Therefore, we propose the 
following model for nephrocalcinosis in the RCALC2 model. In cells of animals with the 
Polg2
+/Y265X
 mutation some interaction will still occur between the wild-type POLG2 and 
POLG protein, but this may not be as efficient as the mutant POLG2 is unlikely to be 
transcribed, which results in reduced total mtDNA. Genes involved in mitochondrial-specific 
processes such as Gpd2 and several mitochondrial ribosomal proteins, which encode essential 
enzymes and proteins involved in protein synthesis within the mitochondrion are 
differentially expressed (Table S3 and Fig. 3). These changes may contribute to the increased 
ROS observed in plasma samples from Polg2
+/Y265X
 mice (Fig. 4), which may cause injury to 
cells allowing sites for crystal retention to develop
(43)
. These changes could then include 
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inflammation, as evidenced by differential expression of genes involved in: inflammation 
(e.g. Apom, alanyl aminopeptidase (Anpep), Apolipoprotein C-I (ApocI) and Pmxp4); and the 
complement component pathway (e.g. C1qb, C1qc, and C3) (Table S3 and Fig. 3). In 
conclusion, the RCALC2 mouse, which is associated with a nonsense mutation in POLG2 
represents a model of idiopathic renal calcification and provides an in vivo resource for 
further mechanistic studies of abnormalities of renal calcium deposition. 
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TABLES  
Table 1
 Analysis of Polg2 Y265X and Acap1 Q419K variants in RCALC2 mice 
 
 
 
 
 
 
The Polg2-Y265X and Acap1-Q419K variants were investigated in the 85 G2 and 138 G3 
mice. Inheritance of the Polg2 mutation co-segregated with the RCALC2 phenotype observed 
in G2 and G3 mice, indicating that this is the causative mutation. In contrast, the Acap1 
variant did not co-segregate with the RCALC2 phenotype indicating that this is not the 
causative mutation for the phenotype.   
 
Genotype 
 
Generation 
 Renal Papillary Calcification 
  Present  Absent 
Polg2
+/Y265X 
 G2 (n = 43)  36 (84%)  7 (16%) 
  G3 (n = 72)  51 (71%)   21 (29%) 
Polg2
+/+ 
 G2 (n = 42)  7 (17%)  35 (83%) 
  G3 (n = 66)  9 (14%)  57 (86%) 
Acap1
+/Q419K 
 G2 (n = 44)  22 (50%)  22 (50%) 
Acap1
+/+
  G2 (n = 41)  20 (49%)  21 (51%) 
27 
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Table 2. Plasma biochemical studies of Polg2
+/Y265X
 (mutant) and Polg2
+/+
 (wild-
type, WT) mice 
 Male  Female 
 Polg2
+/+ 
 Polg2
+/Y265X
  Polg2
+/+
  Polg2
+/Y265X
 
 n=19  n=17  n=11  n=14 
Sodium (mmol/L) 154.32±2.40  154.71±2.54  151.36±1.21  151.21±1.67 
Potassium (mmol/L) 6.15±0.59  6.55±0.83  6.15±0.84  6.08±0.78 
Calcium (mmol/L)
a
 2.32±0.07  2.31±0.05  2.38±0.10  2.34±0.09 
Chloride (mmol/L) 115.05±1.72  116.18±2.46  114.73±1.19  115.43±1.87 
Urea (mmol/L) 8.89±1.70  8.25±1.33  7.39±1.03  6.85±0.90 
Creatinine (µmol/L) 33.79±5.44  33.57±4.26  37.36±4.41  33.57±5.12 
Glucose (mmol/L) 9.65±3.59  9.70±2.45  10.89±1.04  10.05±0.97 
Phosphate (mmol/L) 2.77±1.00  2.77±1.00  2.08±0.44  2.20±0.43 
ALP (U/L) 48.24±5.71  48.24±5.71  78.00±18.53  87.64±19.43 
 
Plasma biochemical analysis was performed on adult (16-week-old) wild-type (Polg2
+/+
) and 
RCALC2 (Polg2
+/Y265X
) mice. All values are expressed as mean±SD. ALP = alkaline 
phosphatase activity. 
a
Plasma calcium concentrations were adjusted for the plasma albumin 
concentration. 
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Table 3.  Urine biochemical studies of Polg2
+/Y265X
 (mutant) and Polg2
+/+
 (wild-type, 
WT) mice 
 Male  Female 
 Polg2
+/+ 
 Polg2
+/Y265X
  Polg2
+/+
  Polg2
+/Y265X
 
 n=19  n=17  n=11  n=14 
Urine output (ml/24 hr) 2.20±0.65  2.14±0.45  1.43±0.46  1.55±0.40 
Fractional excretion calcium 0.003±0.001  0.004±0.002  0.005±0.002  0.005±0.003 
Fractional excretion phosphate 0.14±0.72  0.17±0.25  0.11±0.04  0.11±0.07 
Oxalate/ creatinine  0.22±0.01  0.29±0.10  0.19±0.03  0.19±0.05 
01 
Protein (mg/dl) 982.86±406.74  960.59±218.19  465.25±146.75  401.04±87.49 
 
Urine biochemical analysis was performed on adult (16-week-old) wild-type (Polg2
+/+
) and 
RCALC2 (Polg2
+/Y265X
) mice, in metabolic cages, using urine samples collected over a 24-
hour period. All values are expressed as mean±SD. 
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FIGURE LEGENDS 
Fig. 1  Identification of the Polg2-Y265X Mutation in RCALC2 Mice 
(A) Histological sections of the kidneys of RCALC2 mice and unaffected littermates stained 
with: haematoxylin and eosin, to detect tissue morphology; and von Kossa, to detect calcium 
deposits. Renal papillary images are displayed at the top and renal cortex at the bottom for 
each stain. Gross morphological changes were absent in RCALC2 mouse kidneys. 
Calcification was predominantly of papillary origin, but was also located in the kidney cortex 
of some affected RCALC2 mice. Scale = 10μm. (B) Haplotype analysis of 39 G2 RCALC2 
mice. Each box represents the genotype for the polymorphic locus. Filled box, BALB/c 
allele; open box, C3H allele. The number of mice that displayed each haplotype is indicated 
below each column. Analysis localized the RCALC2 locus to a ~16Mb region between 
D11Mit132 and D11Mit214, on mouse chromosome 11. (C) DNA sequence analysis of Polg2 
in DNA extracted from an unaffected (wild-type, WT) and an RCALC2 (mutant) mouse, 
confirmed the whole-exome analysis result of a heterozygous C-to-A transversion in codon 
265 in RCALC2 mice, that predicted an alteration of the WT tyrosine (Tyr) to a premature 
stop codon, and to result in gain of a HindIII restriction enzyme site. (D) HindIII restriction 
enzyme digestion of PCR products was used to confirm the presence, or absence, of the 
Tyr265Stop (Y265X) mutation in mutant  RCALC2 G2 mice and WT mice, respectively 
(n=5 of each shown). The presence of the HindIII restriction site, results in 2 mutant products 
(bands). RCALC2 mice are observed to have 3 bands, comprising a WT band of 359bp and 2 
mutant bands of 188bp and 171bp; thus RCALC2 mice are heterozygous for the WT and 
mutant alleles. In contrast, the WT mice have only one band at 359bp and are therefore 
homozygous for the WT allele. S = DNA size marker.  
 
Fig. 2  Effect of the Polg2
+/Y265X
 mutation on cDNA and protein expression 
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 (A) Renal expression of Polg2 was assessed in Polg2
+/+
 and Polg2
+/Y265X
 mice using qRT-
PCR (n=4-5 mice for each). All data was normalized to the geometric mean of three 
housekeeper genes, Ccnd1, Ccnd2 and Actb, and expressed as a fold-change relative to that in 
Polg2
+/+ 
mice. ΔCT values are included in Table S4.  (B-C) Western blot analysis of: (B) 
POLG2 and (C) POLG and the housekeeper gene calnexin, which was used as a loading 
control, in whole kidney lysates of 4 Polg2
+/+
 and 4 Polg2
+/Y265X
 mice using an antibody 
targeting the N-terminal region of Polg2. Smaller products were not observed for POLG2, 
indicating that a truncated protein is not present in the mouse kidneys. (Bottom) 
Densitometric analysis of POLG2 and POLG from Western blot analyses. Histograms are 
presented as mean±SEM. Statistical analyses using Student’s t-test, comparing Polg2+/+ and 
Polg2
+/Y265X
 mice for panels A, C and D. *p<0.05. Full Western blots are shown in Fig. S4.  
 
Fig. 3   Assessment of gene expression by qRT-PCR analysis 
(A) The mtDNA content of kidneys from Polg2
+/+
 and Polg2
+/Y265X
 mice was assessed by 
qRT-PCR analysis using mt-Nd1 as a representative gene of mtDNA, and Actb as a nuclear 
housekeeper gene. Data is expressed as the ratio of mt-Nd1 and Actb. N = 4 mice for each 
group. Statistical analyses were performed by student’s t-test comparing Polg2+/+ and 
Polg2
+/Y265X
 mice, *p<0.05. The levels of mtDNA in Polg2
+/Y265X
 mice were significantly 
reduced, compared to Polg2
+/+
 mice. (B-H) Validation of differentially expressed genes from 
cDNA microarray analysis of kidney lysates from Polg2
+/+
 and Polg2
+/Y265X
 mice by qRT-
PCR analysis. Renal expression of: (B) Ube2c, (C) c1qc, (D) c3, (E) Apom, (F) Pxmp4, (G) 
Mrpl3, (H) Gpd2 genes, in cDNA from Polg2
+/+
 and Polg2
+/Y265X
 mice. N=4-5 mice for each 
group. ΔCT values are included in Table S4.  Histograms are presented as mean±SEM. 
Statistical analyses were performed by student’s t-test, *p<0.05, **p<0.02.  
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Fig. 4.   Assessment of mitochondrial function and apoptosis in Polg2
+/Y265X
 mice 
(A) Reactive oxygen species (ROS) production in plasma samples from Polg2
+/+
 and 
Polg2
+/Y265X
 mice. ROS production was significantly higher in plasma from Polg2
+/Y265X
 mice 
compared to Polg2
+/+
 mice. Data is expressed as a fold change compared to Polg2
+/+
 WT 
mice. N = 4 mice for each group. (B-C) Assessment of cDNA transcript levels of the Ndufa1 
and Ndufa4 genes, which are involved in (B) oxidative phosphorylation, and (C) the Acadm 
gene, which is involved in β-oxidation, in cDNA from Polg2+/+ and Polg2+/Y265X mice by 
qRT-PCR analysis. N = 4 mice for each group.  (D) Assessment of cDNA transcript levels of 
the Cycs, Casp3 and Casp9 genes, which are involved in apoptosis, in cDNA from Polg2
+/+
 
and Polg2
+/Y265X
 mice by qRT-PCR analysis. N = 4 mice for each group. (E) Induction of 
active caspase 3/7 in kidneys from Polg2
+/+
 and Polg2
+/Y265X
 mice measured by the 
CaspaseGlo luminescence assay. N=10 mice for each group. No significant difference was 
seen between the two groups. (F) Assessment of cDNA transcript levels of the Ucp2 and 
Timd4 genes, which are involved in phagocytosis in cDNA from Polg2
+/+
 and Polg2
+/Y265X
 
mice by qRT-PCR analysis. N = 4 mice for each group. ΔCT values are included in Table S4.   
Histograms are presented as mean±SEM for all panels. Statistical analyses were performed 
by Student’s t-test. *p<0.05, **p<0.01 and ***p<0.001.      
